Kiko Taganashi - TAGANASHI DESIGN

Savara Inc.

Pulrysta Nebulizer Branding

Molgramostim, an inhaled nebulized solution to treat pulmonary alveolar proteinosis (PAP) that was in preparation for Phase III study. The Companies interim CCO who was in charge overseeing the Phase III trial contacted Sampson & Company to rebrand when and if the nebulizer would pass the trial successfully. Pulrysta was the name that Savara's committee agreed on.

I was tasked on creating final branding artwork that expressed the results of the medication; the ability to breath clearly. After many iterations on this metaphor, the final artwork as you see below was chosen by Savara for their product.

Final Pulrysta branding

Final Pulrysta packaging artwork